120 related articles for article (PubMed ID: 30546900)
1. Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report.
Sekine A; Katano T; Oda T; Ikeda S; Iwasawa T; Satoh H; Kataoka T; Okudela K; Ogura T
Mol Clin Oncol; 2018 Dec; 9(6):673-676. PubMed ID: 30546900
[TBL] [Abstract][Full Text] [Related]
2. [Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].
Li L; Zhou L; Zhang J
Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):798-804. PubMed ID: 31874677
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
4. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.
Sekine A; Kato T; Hagiwara E; Shinohara T; Komagata T; Iwasawa T; Satoh H; Tamura K; Kasamatsu T; Hayashihara K; Saito T; Takahashi H; Ogura T
Lung Cancer; 2012 Jul; 77(1):64-9. PubMed ID: 22335887
[TBL] [Abstract][Full Text] [Related]
5. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
6. Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation.
Schaller A; Beau-Faller M; Mennecier B; Renaud-Picard B; Weingertner N; Massard G; Quoix E
Case Rep Oncol; 2014; 7(3):769-73. PubMed ID: 25722667
[TBL] [Abstract][Full Text] [Related]
7. Afatinib for the treatment of metastatic non-small cell lung cancer.
Joshi M; Rizvi SM; Belani CP
Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
[TBL] [Abstract][Full Text] [Related]
8. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
Okuma Y; Kashima J; Watanabe K; Homma S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1601-1611. PubMed ID: 29858682
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
11. Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.
Hsu F; Nichol A; Toriumi T; De Caluwe A
Acta Oncol; 2017 Sep; 56(9):1175-1180. PubMed ID: 28521651
[TBL] [Abstract][Full Text] [Related]
12. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
Hong W; Wu Q; Zhang J; Zhou Y
Oncol Lett; 2019 Oct; 18(4):3887-3895. PubMed ID: 31516600
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
[No Abstract] [Full Text] [Related]
15. Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report.
Otoshi R; Sekine A; Okudela K; Katano T; Asaoka M; Ikeda S; Baba T; Komatsu S; Hagiwara E; Takashi O
Mol Clin Oncol; 2020 Jul; 13(1):80-82. PubMed ID: 32454978
[TBL] [Abstract][Full Text] [Related]
16. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
18. Brain metastases in patients with non-small cell lung cancer: the role of mutated-
Hsiao SH; Chou YT; Lin SE; Hsu RC; Chung CL; Kao YR; Liu HE; Wu CW
Oncotarget; 2017 Aug; 8(32):53405-53418. PubMed ID: 28881820
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma of the Lung with Miliary Metastases and Primary Resistance Exon 20 Mutations.
Hsu F
Cureus; 2018 Oct; 10(10):e3533. PubMed ID: 30648067
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
